Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry
Main finding · MACE, incidence per 100 patient-yearsResult — go to the resultAdjusted hazard ratio 1.36 95% CI 0.62–2.96Authors' conclusion
In a real-life setting, there is no increase in MACEs or cancers in users of JAKis compared with TNFis.
Study context
- Population
- RA patients who had ever used Janus kinase (JAKis) or TNFis, Hong Kong Biologics Registry 2008–2021 (83.7% women, age 53.8 [12.5] years)courses in 1732 RA patients
- Participants
- 2,471 patients
- Exposure
- JAKi vs TNFi in RA
- Outcome
- Incidence of MACE, cancer and infections
Methodological detailsregistry-based, adjusted for confounding factors
- Registry-based
- Adjusted for confounding factors
Main finding
MACE, incidence per 100 patient-years
Adjusted hazard ratio
1.36
95% CI 0.62–2.96
P = 0.44
Events by group
JAKivs TNFi
aHR 1.36 (95% CI 0.62–2.96); P = 0.44
As reported in the abstract
Observational data: associations, not effects.
Further findings
Cancer, incidence per 100 patient-years
P = 0.25
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| Cancer, incidence per 100 patient-years | 0.87 (0.39–1.95) | P = 0.74 | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Safety
Infections, rate per 100 patient-years
P = 0.02
Herpes zoster, rate per 100 patient-years
P < 0.001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford). Published 2 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →